In addition, we have demonstrated a role of the FBP1/STAT3 axis in the functions of β‐elemene in gefitinib‐resistant NSCLC (Figure 7), which may be a promising target for therapeutic intervention in patients with gefitinib resistance. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.